KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to -$35.0 million.

  • Nektar Therapeutics' Net Income towards Common Stockholders rose 558.33% to -$35.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.4 million, marking a year-over-year increase of 3263.14%. This contributed to the annual value of -$119.0 million for FY2024, which is 5689.72% up from last year.
  • Latest data reveals that Nektar Therapeutics reported Net Income towards Common Stockholders of -$35.0 million as of Q3 2025, which was up 558.33% from -$39.2 million recorded in Q2 2025.
  • Nektar Therapeutics' Net Income towards Common Stockholders' 5-year high stood at $7.2 million during Q4 2024, with a 5-year trough of -$159.1 million in Q2 2022.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$52.4 million (2024), whereas its average is -$74.5 million.
  • In the last 5 years, Nektar Therapeutics' Net Income towards Common Stockholders crashed by 5689.88% in 2021 and then soared by 11719.15% in 2024.
  • Over the past 5 years, Nektar Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$146.9 million in 2021, then skyrocketed by 54.66% to -$66.6 million in 2022, then surged by 36.82% to -$42.1 million in 2023, then skyrocketed by 117.19% to $7.2 million in 2024, then tumbled by 583.66% to -$35.0 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$35.0 million for Q3 2025, versus -$39.2 million for Q2 2025 and -$46.4 million for Q1 2025.